Mid-Atlantic BioTherapeutics
Doylestown
About Mid-Atlantic BioTherapeutics
Mid-Atlantic BioTherapeutics they are focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. They are actively addressing the growing antibiotic resistance problems and creating a revolutionary treatment paradigm for viral diseases (e.g., the Tamiflu alternative for influenza), emerging infectious diseases, and biodefense.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $5.0M
- Last round: Series Unknown (Aug 2025)
- Website: mabt.us
- Phone: (215) 266-2301
Industries & Categories
Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/mid-atlantic-biotherapeutics-145750 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.